Drug intelligence / Profile preview

valomaciclovir

Development stage: Phase 2
Modality: Small Molecules
Administration: Oral

Overview

Valomaciclovir is a prodrug of the acyclic guanosine derivative omaciclovir. It exhibits antiviral activity against varicella zoster virus (VZV) and other members of the herpesvirus family. After administration, valomaciclovir is converted in vivo to omaciclovir, which acts as a nucleoside analog inhibitor of VZV DNA polymerase. This mechanism disrupts viral DNA synthesis and replication. Valomaciclovir has reached up to phase II clinical trials and has at least one investigational indication[5].

Other names: valomaciclovir [INN]

Targets

DNA polymerase family

Beyond the preview

Go deeper on valomaciclovir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on valomaciclovir.

Explore the full profile